Study summary
An antibody built for a rare gene fusion shrank tumors in almost half of pancreatic cases that have it
42%tumors shrank in NRG1-fusion pancreatic cancer
What was tested
Zenocutuzumab, an antibody for cancers driven by an NRG1 gene fusion (found in roughly 1% of pancreatic cancers), tested across 12 tumor types including pancreatic cancer.
What they found
- Tumors shrank in 15 of 36 people (42%) with NRG1-fusion pancreatic cancer, and in 29% of NRG1-fusion lung cancers.
- Responses lasted a median of 11.1 months.
- Side effects were mostly mild: diarrhea, fatigue and infusion reactions.
What it means
Approved for any NRG1 fusion-positive cancer. Worth testing for in pancreatic cancer, since it is rare but has a real treatment.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.